Literature DB >> 15609895

Genetics in melanoma.

Shy Stahl1, Eran Bar-Meir, Eitan Friedman, Eli Regev, Arie Orenstein, Eyal Winkler.   

Abstract

Melanoma is the leading cause of death from skin tumors worldwide, with an annual increase in incidence over the past decade. The molecular mechanisms involved in melanoma pathogenesis are beginning to be unraveled. While a family history of melanoma and exposure to ultraviolet irradiation have been known for years as risk factors in melanoma development, the precise genes involved in inherited predisposition were defined only in the past decade. Germline mutations in two genes that play a pivotal role in controlling cell cycle and division--CDKN2A and cyclin-dependent kinase 4 (CDK4)--have been detected in autosomal, dominant, high penetrance familial melanoma cases. In addition to these two highly penetrant genes, germline mutations and polymorphisms in a few low penetrance genes have been reported in familial melanoma cases: melanocortin-1 receptor, epidermal growth factor, glutathione s-transferase M1, cytochrome p450 debrisoquine hydroxylase locus (CYP2D6) and vitamin D receptor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15609895

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  6 in total

1.  Proteomic analyses of the Xiphophorus Gordon-Kosswig melanoma model.

Authors:  Amy N Perez; Lee Oehlers; Shelia J Heater; Rachell E Booth; Ronald B Walter; Wendi M David
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2011-06-06       Impact factor: 3.228

2.  Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma.

Authors:  Li-E Wang; Yu-jing Huang; Ming Yin; Jeffrey E Gershenwald; Victor G Prieto; Jeffrey E Lee; Madeleine Duvic; Elizabeth A Grimm; Qingyi Wei
Journal:  Eur J Cancer       Date:  2010-07-23       Impact factor: 9.162

3.  Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin.

Authors:  Luna Kadouri; Mark Temper; Tal Grenader; Dvorah Abeliovich; Tamar Hamburger; Tamar Peretz; Michal Lotem
Journal:  Fam Cancer       Date:  2008-08-05       Impact factor: 2.375

4.  NRG1 / ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation.

Authors:  Kristina Buac; Mai Xu; Julie Cronin; Ashani T Weeraratna; Stephen M Hewitt; William J Pavan
Journal:  Pigment Cell Melanoma Res       Date:  2009-07-30       Impact factor: 4.693

5.  The association between Parkinson's disease and melanoma: a systematic review and meta-analysis.

Authors:  Pei Huang; Xiao-Dong Yang; Sheng-Di Chen; Qin Xiao
Journal:  Transl Neurodegener       Date:  2015-11-03       Impact factor: 8.014

Review 6.  Parkinson's Disease and Melanoma: Co-Occurrence and Mechanisms.

Authors:  Anindita Bose; Gregory A Petsko; David Eliezer
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.